GSK presents the application for registration for albiglutide in Europe.
Madrid, March of 2013- GlaxoSmithKline (GSK) announced the filing of the application for marketing authorization for albiglutide with the name of EPERZAN ® to the European Medicines Agency (EMA). Albiglutide is a treatment research of weekly doses for adults with type 2 diabetes mellitus, which is not yet approved anywhere in the world. On January 14, 2013, GSK announced the presentation of an application for registration in the United States.
Albiglutide
Albiglutide, a GLP-1 receptor agonist, is a biological investigational drug for the treatment of diabetes type 2, designed for subcutaneous administration once a week. Normally GLP-1 is a peptide that is secreted in the gastrointestinal tract during the meal, that at the same time helps to release insulin to control the increase in blood sugar after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or does not occur. GLP-1 is rapidly degraded and albiglutide is designed to have a longer duration of action being composed of two copies of GLP-1 human modified merged into series to human albumin.
GlaxoSmithKline (GSK), one of the companies leading world pharmaceutical research and health care, is committed to improving the quality of people’s life, enabling people to have more vitality, feel better and live longer.
